WO2005121320A1 - 幹細胞自己複製促進剤 - Google Patents
幹細胞自己複製促進剤 Download PDFInfo
- Publication number
- WO2005121320A1 WO2005121320A1 PCT/JP2005/010642 JP2005010642W WO2005121320A1 WO 2005121320 A1 WO2005121320 A1 WO 2005121320A1 JP 2005010642 W JP2005010642 W JP 2005010642W WO 2005121320 A1 WO2005121320 A1 WO 2005121320A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- activity
- active oxygen
- stem cells
- substance
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 225
- 230000010076 replication Effects 0.000 title abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 140
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 140
- 239000001301 oxygen Substances 0.000 claims abstract description 140
- 230000000694 effects Effects 0.000 claims abstract description 117
- 239000000126 substance Substances 0.000 claims abstract description 106
- 238000004519 manufacturing process Methods 0.000 claims abstract description 40
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 230000003449 preventive effect Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 8
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 88
- 230000003078 antioxidant effect Effects 0.000 claims description 55
- 210000001519 tissue Anatomy 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 50
- 102000000872 ATM Human genes 0.000 claims description 48
- 108090000790 Enzymes Proteins 0.000 claims description 48
- 102000004190 Enzymes Human genes 0.000 claims description 47
- 239000003963 antioxidant agent Substances 0.000 claims description 47
- 230000001737 promoting effect Effects 0.000 claims description 47
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 claims description 44
- 241000699670 Mus sp. Species 0.000 claims description 43
- 230000002950 deficient Effects 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 34
- 230000031146 intracellular signal transduction Effects 0.000 claims description 34
- 230000000069 prophylactic effect Effects 0.000 claims description 34
- 229940124597 therapeutic agent Drugs 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 22
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 21
- 230000006378 damage Effects 0.000 claims description 19
- 238000001415 gene therapy Methods 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 claims description 18
- 230000002708 enhancing effect Effects 0.000 claims description 17
- 210000002919 epithelial cell Anatomy 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 14
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims description 14
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 13
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 13
- 235000018417 cysteine Nutrition 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 10
- 102000001267 GSK3 Human genes 0.000 claims description 10
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 10
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 10
- 235000021466 carotenoid Nutrition 0.000 claims description 9
- 150000001747 carotenoids Chemical class 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 9
- 229940035936 ubiquinone Drugs 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical group 0.000 claims description 8
- 235000013824 polyphenols Nutrition 0.000 claims description 8
- 210000003491 skin Anatomy 0.000 claims description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 7
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 7
- 235000012754 curcumin Nutrition 0.000 claims description 7
- 239000004148 curcumin Substances 0.000 claims description 7
- 229940109262 curcumin Drugs 0.000 claims description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 7
- 102000016938 Catalase Human genes 0.000 claims description 6
- 108010053835 Catalase Proteins 0.000 claims description 6
- 108010016626 Dipeptides Proteins 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 102000003992 Peroxidases Human genes 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 210000003714 granulocyte Anatomy 0.000 claims description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 210000001772 blood platelet Anatomy 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 210000003904 glomerular cell Anatomy 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 210000002997 osteoclast Anatomy 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 210000002556 adrenal cortex cell Anatomy 0.000 claims description 3
- 210000001943 adrenal medulla Anatomy 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 claims description 3
- 210000001339 epidermal cell Anatomy 0.000 claims description 3
- 210000002907 exocrine cell Anatomy 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 210000000442 hair follicle cell Anatomy 0.000 claims description 3
- 210000001865 kupffer cell Anatomy 0.000 claims description 3
- 210000004216 mammary stem cell Anatomy 0.000 claims description 3
- 210000004498 neuroglial cell Anatomy 0.000 claims description 3
- 210000004248 oligodendroglia Anatomy 0.000 claims description 3
- 210000000963 osteoblast Anatomy 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 230000001817 pituitary effect Effects 0.000 claims description 3
- 210000002955 secretory cell Anatomy 0.000 claims description 3
- 210000004927 skin cell Anatomy 0.000 claims description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 210000003454 tympanic membrane Anatomy 0.000 claims description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 210000001053 ameloblast Anatomy 0.000 claims description 2
- 210000002449 bone cell Anatomy 0.000 claims description 2
- 210000003890 endocrine cell Anatomy 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 108091008695 photoreceptors Proteins 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 2
- QVGXLLKOCUKJST-IGMARMGPSA-N oxygen-16 atom Chemical compound [16O] QVGXLLKOCUKJST-IGMARMGPSA-N 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 210000002754 ksl cell Anatomy 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000009758 senescence Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 7
- 101150065175 Atm gene Proteins 0.000 description 7
- 229960004308 acetylcysteine Drugs 0.000 description 7
- -1 flavan-3-oneole Natural products 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 208000019229 Spleen disease Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 208000027140 splenic disease Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000032677 cell aging Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 210000000267 erythroid cell Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150029662 E1 gene Proteins 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010062867 Lenograstim Proteins 0.000 description 2
- 238000011779 Ly5.1 mouse Methods 0.000 description 2
- 206010061296 Motor dysfunction Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229950010676 nartograstim Drugs 0.000 description 2
- 108010032539 nartograstim Proteins 0.000 description 2
- 230000009707 neogenesis Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 229930013783 (-)-epicatechin Natural products 0.000 description 1
- 235000007355 (-)-epicatechin Nutrition 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- ZLCOWUKVVFVVKA-WDSKDSINSA-N (2r)-3-[[(2r)-2-acetamido-2-carboxyethyl]disulfanyl]-2-aminopropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSSC[C@H](N)C(O)=O ZLCOWUKVVFVVKA-WDSKDSINSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- JLHWBVQBEGDSEZ-LFOOZZFTSA-N (4s)-5-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-5-amino-1-[[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phosphonooxypropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]p Chemical compound CCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H](C)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](COP(O)(O)=O)C(=O)N2[C@@H](CCC2)C(N)=O)CCC1 JLHWBVQBEGDSEZ-LFOOZZFTSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NTSBZVCEIVPKBJ-UHFFFAOYSA-N 1-azakenpaullone Chemical compound C1C(=O)NC2=CC=CN=C2C2=C1C1=CC(Br)=CC=C1N2 NTSBZVCEIVPKBJ-UHFFFAOYSA-N 0.000 description 1
- LVFFZQQWIZURIO-UHFFFAOYSA-N 2-phenylbutanedioic acid Chemical compound OC(=O)CC(C(O)=O)C1=CC=CC=C1 LVFFZQQWIZURIO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 description 1
- IMCMOBYGKAJDGW-UHFFFAOYSA-N 3,4-bis(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrole-2,5-dione Chemical class C1=CN=C2NC(C=3C(=O)NC(C=3C=3NC4=NC=CC=C4C=3)=O)=CC2=C1 IMCMOBYGKAJDGW-UHFFFAOYSA-N 0.000 description 1
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 1
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101100313164 Caenorhabditis elegans sea-1 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- UFCLZKMFXSILNL-PSEXTPKNSA-N Isochlorogenic acid b Chemical compound O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 108010063250 N-myristoyl-glycyl-lysyl-glutamyl-alanyl-prolyl-prolyl-alanyl-prolyl-prolyl-glutaminyl-phosphoseryl-proline Proteins 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- BLQKIGOLRJPVAW-RXSVEWSESA-N OP(O)(=O)OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O Chemical compound OP(O)(=O)OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O BLQKIGOLRJPVAW-RXSVEWSESA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004216 Rhodoxanthin Substances 0.000 description 1
- VWXMLZQUDPCJPL-ZDHAIZATSA-N Rhodoxanthin Chemical compound CC\1=CC(=O)CC(C)(C)C/1=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C1\C(C)=CC(=O)CC1(C)C VWXMLZQUDPCJPL-ZDHAIZATSA-N 0.000 description 1
- VWXMLZQUDPCJPL-XPZLFLLQSA-N Rhodoxanthin Natural products O=C1C=C(C)/C(=C\C=C(/C=C/C=C(\C=C\C=C\C(=C/C=C/C(=C\C=C\2/C(C)=CC(=O)CC/2(C)C)/C)\C)/C)\C)/C(C)(C)C1 VWXMLZQUDPCJPL-XPZLFLLQSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- VWXMLZQUDPCJPL-JCFHCUBBSA-N all-trans-Rhodoxanthin Natural products CC(=C/C=C/C(=C/C=C/1C(=CC(=O)CC1(C)C)C)/C)C=CC=CC(=CC=CC(=CC=C2/C(=CC(=O)CC2(C)C)C)C)C VWXMLZQUDPCJPL-JCFHCUBBSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000011121 diffuse pulmonary fibrosis Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960005469 hydroxocobalamin acetate Drugs 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000019246 rhodoxanthin Nutrition 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000011722 γ-tocotrienol Substances 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a stem cell self-renewal promoting agent, a prophylactic agent for cancer, a prophylactic or therapeutic agent for a disease or tissue dysfunction accompanied by tissue destruction, a stem cell culture medium to which the stem cell self-renewal promoting agent is added,
- the present invention relates to a stem cell cultured in a medium, a method for producing a stem cell, and a method for screening a hematopoietic stem cell self-renewal promoter.
- Cells produced by such a stem cell system include, in addition to blood cells, skin epithelial cells, corneal epithelium, nervous system cells, alveolar epithelial cells, tracheal epithelial cells, gastrointestinal mucosal cells, hepatocytes, spleen endocrine, There are exocrine cells, salivary gland cells, blood vessels, mesenchymal tissues such as skeletal muscle and bone, renal tubular epithelial cells, renal glomerular cells, testicular germ cells, and the like.
- Mitotic senescence is a phenomenon in which normal cells stop cell division after a limited number of divisions. Cells that have ceased cell division change their morphology significantly and eventually induce cell death. It has been shown that the molecular mechanism of such mitotic senescence is caused by shortening of the telomere at the end of the chromosome. (See Non-Patent Document 5).
- Ataxia telangiectasia is an ataxia telangiectasia (AT) that exhibits progressive cerebellar ataxia, telangiectasia of the ocular mucosa and skin, and is highly susceptible to infection.
- AT is autosomal recessive and affects men and women.
- IgG2, IgG4, IgA, and IgE decreased antibody production against polysaccharide antigens, decreased T cell numbers, and dysfunction were observed.
- defects have been observed in radiation sensitivity, DNA repair capacity, and cell cycle monitoring of cells.
- stress-induced aging has been proposed as another hypothesis of cell aging. Unlike programmed aging, such as mitotic aging, when cells are exposed to long-term stress, the stress-induced DNA damage accumulates and cell aging occurs. It is a hypothesis that it will occur (see Non-Patent Document 9). Oxidative stress, ultraviolet rays, and chemicals are considered as stresses on cells. In C. elegans, mutations in the insulin / IGF-I signal pathway were observed to promote the transcription of antioxidant enzymes such as superoxide dismutase (SOD) by extending the activity of the forkhead transcription factor, extending the lifespan.
- SOD superoxide dismutase
- Non-Patent Document 10 It is the mitochondrial electron transport system that produces the most active oxygen in cells, and in humans and other mammals, skeletal muscle and liver are thought to play a central role in producing active oxygen. It is also believed that continuous exposure of macrophages to reactive oxygen species associated with chronic inflammation promotes cell senescence. It is thought that these active oxygens not only lead the cells to senescence, but also activate the oncogenes due to DNA damage and induce cancer cells instead of senescence in stem cells. However, in bone marrow stem cells, skeletal muscle and liver-derived active oxygen and inflammation The likelihood of exposure to reactive oxygen species derived from macrophages is low, and it is difficult to explain stem cell senescence in "stress-induced senescence".
- Non-Patent Document 1 "Journal of Clinic al Investigation", 2004, Vol. 113, p. 4-7
- Non-Patent Document 2 "Journal of Clinic al Investigation", 2004, Vol. 113, p. 16-168
- Non-Patent Document 3 "Journal of Clinic al Investigation", 2004, Vol. 113, p. 175-179
- Non-Patent Document 4 "Etamental Cell Research", 19961, Vol. 25, p. 585-621
- Non-Patent Document 5 “Nature”, 1990, Vol. 345, p. 458-460
- Non-Patent Document 6 “Nature Review Cancer Journal", 2003, Volume 3, p. 155—168
- Non-Patent Document 7 “Nature”, 2003, Vol. 421, p. 643-648
- Non-patent Document 8 “Journal of Clinic al Investigation” ) ", Vol. 113, p. 4-7, 2004
- Non-Patent Document 9 "Physiological Reviews", 2002, Vol. 82, p. 47-95
- Non-Patent Document 10 “Trend in Biochemical Sciences”, 2002, Vol. 27, p. 352—360
- the present invention provides a stem cell self-renewal promoting agent, a prophylactic agent for cancer, a prophylactic or therapeutic agent for a disease associated with tissue destruction or tissue failure, a medium for stem cell culture to which the stem cell self-renewal promoting agent is added,
- An object of the present invention is to provide a stem cell cultured in the medium, a method for producing the stem cell, or a method for screening a hematopoietic stem cell self-renewal promoter.
- the present invention relates to the following (1) to (32).
- (1) In stem cells, the activity to suppress the production of active oxygen, the activity to reduce active oxygen in stem cells by eliminating the generated active oxygen, and the intracellular signal transduction system induced by the active oxygen
- the activity to suppress the production of active oxygen the activity to reduce active oxygen in stem cells by eliminating the generated active oxygen, and the intracellular signal transduction system induced by the active oxygen
- the activity of suppressing the production of active oxygen the activity of reducing active oxygen in stem cells by eliminating the generated active oxygen, and the intracellular signal transduction system induced by the active oxygen
- antioxidant enzyme is an enzyme selected from the group consisting of catalase, daltathione peroxidase, daltathione reductase, and superoxide dismutase.
- the substance having the ability to induce the expression of antioxidant enzyme and enhance the activity of Z or the activity of the antioxidant enzyme is a gene therapy vector into which a gene encoding the antioxidant enzyme has been introduced.
- the agent for promoting self-renewal of stem cells according to (4) or (5) which is a substance having the ability to induce expression of antioxidant enzymes and enhance Z or the activity of the antioxidant enzymes, caratonin.
- a substance having at least one activity of reducing active oxygen in the stem cell by removing the active oxygen and removing the intracellular signal transduction system induced by the active oxygen is added to the stem cells by the Ataxia 'Terranectasia' mu.
- the agent for promoting self-renewal of stem cells according to the above (1) which is a substance capable of inducing the expression of a titid (Ataxia telangiectasia muted, hereinafter referred to as “ATM”) protein and enhancing the activity of Z or ATM protein.
- the agent for promoting self-renewal of stem cells according to (8), wherein the substance capable of inducing the expression of ATM protein and enhancing the activity of Z or ATM protein is a vector for gene therapy into which ATM has been introduced.
- a prophylactic agent for cancer comprising as an active ingredient a substance having at least one inhibitory activity.
- a preventive or therapeutic agent for a disease associated with tissue destruction or tissue failure comprising as an active ingredient a substance having at least one inhibitory activity.
- the activity to suppress the production of active oxygen In stem cells, the activity to reduce active oxygen in stem cells by erasing the generated active oxygen, and the intracellular signal transduction system induced by the active oxygen
- a substance having at least one inhibitory activity glycogen synthase kinase-3 (GSK-3) inhibitor; hepatocyte growth factor (HGF); granulocyte colony stimulating factor (G-CSF); macrophage colony stimulating factor (M-CSF) and granulocyte 'macrophage colony stimulating factor (GM-CSF)
- G-CSF glycogen synthase kinase-3
- M-CSF macrophage colony stimulating factor
- GM-CSF granulocyte 'macrophage colony stimulating factor
- Tissues are red blood cells, white blood cells, platelets, fibroblasts, fat cells, skeletal muscle cells, smooth muscle cells, cardiomyocytes, neurons, glia, oligodendrocytes, vascular endothelial cells, skin epidermal cells, skin dermal cells , Hair follicle cells, bone cells, osteoblasts, osteoclasts, chondrocytes, tracheal epithelial cells, alveolar cells, gastrointestinal epithelial cells, oral epithelial cells, ameloblasts, zoegeblasts, hepatocytes, Kupffer cells, Gallbladder epithelial cells, spleen endocrine cells, spleen exocrine cells, renal tubular cells, renal glomerular cells, ureteral epithelial cells, urothelial cells, pituitary secretory cells, thyroid cells, adrenal cortex cells, adrenal medulla cells, prostate The prophylaxis according to the above (13) or (14),
- Substances having antioxidant activity include vitamin B12, vitamin C, vitamin E, carotenoids, ubiquinone, N-acyl derivatives of cysteine, dipeptides or tripeptides containing at least one cysteine, polyphenols, curcumin And the prophylactic or therapeutic agent according to the above (16), which is at least one substance also selected from the group consisting of tetrahydrocurcumin.
- the activity to suppress the production of active oxygen the activity to reduce active oxygen in stem cells by erasing the generated active oxygen, and the intracellular signal transduction system induced by the active oxygen
- the substance having at least one inhibitory activity is a substance capable of inducing the expression of an antioxidant enzyme in the stem cell and enhancing Z or the activity of the antioxidant enzyme.
- the prophylactic or therapeutic agent according to any one of the above.
- the antioxidant enzyme is an enzyme selected from the group consisting of catalase, daltathione peroxidase, daltathione reductase, and superoxide dismutase.
- the gene therapy vector described above, wherein the substance capable of inducing the expression of the antioxidant enzyme and enhancing Z or the activity of the antioxidant enzyme is a gene therapy vector into which a gene encoding the antioxidant enzyme has been introduced.
- the activity to suppress the production of active oxygen the activity to reduce active oxygen in stem cells by eliminating the generated active oxygen, and the intracellular signal transduction system induced by the active oxygen
- the substance having at least one inhibitory activity is a substance capable of inducing the expression of an ATM protein in the stem cells and enhancing the activity of Z or ATM protein.
- the preventive or therapeutic agent according to the above (22), wherein the substance capable of inducing the expression of the ATM protein and enhancing the activity of Z or ATM protein is a vector for gene therapy into which ATM has been introduced.
- prophylactic agent according to any one of (12) to (15) above, wherein the substance having an activity of suppressing an intracellular signal transduction system induced by active oxygen in stem cells is a P38MAPK inhibitor. Therapeutic drugs.
- a prophylactic or therapeutic agent for a disease or tissue failure associated with tissue destruction including stem cells cultured in the medium according to (26).
- stem cells cultured in the medium according to (26).
- the self-renewal ability of cells including hematopoietic stem cells derived from ATM homo-deficient mice was measured, and the cells were tested in the presence and absence of the test substance.
- the self-renewal ability in the presence of the test substance is compared to the self-renewal ability in the absence of the test substance.
- a method for screening a hematopoietic stem cell self-renewal promoter which is characterized in that:
- Stem cells are cultured in the presence of the stem cell self-renewal promoter according to any one of (1) to (11) to promote self-renewal of the stem cells, and the stem cells are collected from the culture.
- a method for producing a stem cell is described in detail below.
- An activity for suppressing the production of active oxygen in stem cells an activity for reducing active oxygen in stem cells by erasing the generated active oxygen, and an activity for producing active agents for promoting self-renewal of stem cells.
- a stem cell self-renewal promoting agent a prophylactic agent for cancer, a prophylactic or therapeutic agent for a disease or tissue failure accompanied by tissue destruction, a medium for stem cell culture to which the stem cell self-renewal promoting agent is added, And a method for producing a stem cell or a method for screening a hematopoietic stem cell self-renewal promoter.
- the agent for promoting self-renewal of stem cells of the present invention has an activity of suppressing the production of active oxygen in stem cells, an activity of reducing active oxygen in stem cells by erasing the generated active oxygen, and an activity of inducing the active oxygen.
- a substance having an activity of suppressing the production of active oxygen and reducing active oxygen by eliminating Z or produced active oxygen includes a substance having an antioxidant effect, an antioxidant enzyme in stem cells.
- ATM Ataxia telangiectasia mutated
- Examples of the substance having an antioxidant effect include vitamin B12, vitamin C, vitamin E, carotenoid, ubiquinone, N-acyl derivative of cysteine, dipeptide or tripeptide containing at least one cysteine, polyphenols , Curcumin, tetrahydrocurcumin and the like.
- vitamin B12 examples include hydroxocobalamin hydrochloride, hydroxocobalamin acetate, hydroxocobalamin, cyanocobalamin, methylcobalamin, ditriconolamin, adenosylconolamin, and acocobalamine.
- vitamin C examples include L-ascorbic acid, sodium L-ascorbate, and stearic acid L-ascorbate.
- vitamin E examples include ⁇ -tocopherolone, j8-tocopherolone, ⁇ -tocopherol, ⁇ -tocopherolone, ⁇ -tocotrienole, j8-tocotrienole, ⁇ -tocotrienol And ⁇ -tocotrienol, and derivatives thereof such as acetates, nicotinic esters and phosphates.
- the carotenoid may be any of a natural product and a synthetic product.
- ⁇ -force roten, / 3 strength strength, ⁇ strength strength strength, astaxanthin , canthaxanthin, zeaxanthin , Lycopene, cryptoxanthin, crocin, rhodoxanthin, rutin, etc. it can.
- an ester of the carotenoid with a fatty acid or the like for example, a monoester or diester of oleic acid, linoleic acid, normitic acid, myristic acid, or the like can also be used.
- ubiquinone those having 1 to 12 isoprene residues in ubiquinone are preferably used, those having 6 to 12 residues are more preferably used, and those having 10 residues ( Ubidecarenone) is particularly preferably used.
- N-acyl derivative of cysteine N-acetyl cysteine is preferably used.
- dipeptide or tripeptide containing at least one cysteine is preferably used.
- polyphenols examples include flavonoids, tannins, caffeic acid, caffeic acid derivatives, lignans, and the like.
- Flavonoids include, for example, flavone, isoflavone, flavonol, flavanone, flavan-3-oneole, catechin, auron, anthocyanidin, force norecon, dihydro force norecon, and more specifically, for example, quercetin, genistein, Rutin, Hesbergin, Silymarin, (+)-Catechin, (-)-Epigallocatechin gallate, (-)-Epicatechin, (-)-Epigallocatechin, (-)-Epi tekine gallate, etc. .
- caffeic acid derivative examples include, for example, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicafoiloquinic acid, and 3,4,5-tricafoiloquinic acid. , Chlorogenic acid, rosmarinic acid and the like.
- lignans examples include sesamin, sesamolin, sesamol, sesaminol, scizandrine, deoxycisandrin, gomisin and the like.
- Examples of the substance capable of inducing the expression of antioxidant enzymes in stem cells and enhancing Z or the activity of the antioxidant enzymes include melatonin and the like. Further, a gene therapy vector into which a gene encoding the antioxidant enzyme has been introduced can be used as a substance having the ability to induce the expression of antioxidant enzyme in stem cells and enhance the activity of Z or the activity of the antioxidant enzyme. .
- antioxidant enzymes include catalase, daltathione peroxidase, and gluta. Thione reductase, superoxide dismutase, and the like.
- Examples of the gene therapy vector include a retrovirus vector and an adenovirus vector.
- the retrovirus vector utilizes a mouse leukemia virus (MoMLV: Moloney murine leukemia virus) as an RNA virus as a vector.
- MoMLV mouse leukemia virus
- the basic structure of the retroviral genome to which MoMLV belongs is the LTR (long terminal repeat) at both ends, the gag, pol, env sandwiched between them, and the ⁇ force between the LTR and gag on the 5 'side.
- the retrovirus vector can be used as a vector for gene therapy according to the method described in Br. Med. Bull. 1995 Jan; 51 (l): 12-30. Vile RG, Russell SJ and the like.
- the vector plasmid is introduced into a packaging cell line designed to express a viral protein (gag, pol gene product), and the cells are cultured.
- Lovirus retroviral vector
- the recombinant retrovirus in the culture can be concentrated by centrifugation.
- an adenovirus vector is a vector derived from an adenovirus which is a DNA virus different from a retrovirus vector.
- the adenovirus vector can be used as a gene therapy vector according to the method described in Curr. Opin. Biotechnol. 1999 Oct; 10 (5): 440-7. Benihoud K, Yeh P, Perricaudet M. That is, in order to use adenovirus as a vector for gene therapy, first, the E1 gene region is deleted from the viral genome consisting of linear double-stranded DNA of about 36 kb, and the above-mentioned antioxidant enzyme is added thereto. Construct a cosmid with one of the genes inserted.
- adenovirus vector By introducing the cosmid into a human fetal kidney-derived cell line (293 cells) that continuously expresses E1A and E1B together with the parental viral DNA obtained by cutting the E1 gene region at multiple locations, Homologous recombination occurs to produce a non-proliferating recombinant adenovirus (adenovirus vector).
- adenovirus vector This recombinant adenovirus vector can be recovered by freeze-thawing the cells.
- Examples of the substance having the ability to induce the expression of the ATM protein in the stem cells and enhance the activity of the Z or ATM protein include, for example, a gene therapy vector into which the ATM has been introduced. Examples of the gene therapy vector include the above-described gene therapy vector and the like.
- Examples of the substance having an activity of suppressing an intracellular signal transduction system induced by active oxygen in stem cells include an inhibitor of P38MAPK and the like.
- P38MAPK is activated by active oxygen, and as a result, self-renewal of stem cells is suppressed. Therefore, a p38MAPK inhibitor suppresses the activation of p38MAPK, thereby suppressing the intracellular signal transduction system, thereby promoting the self-renewal of stem cells.
- Examples of p38 MAPK inhibitors include SB203580 (Journal of Biological Chemistry 272 (18) 121 16-12121, 1997), SB202190 (BIOMOL Research Labs., Inc.) ⁇ PD169316 (Calbiochem), FR167653 (Nikken Chemical Co. , Ltd.) ⁇ BIRB796BS (Blood 101, 4446-4448, 2003).
- an inhibitor of P38MAPK gene expression such as small inhibitory RNA (siRNA) against p38MAPK may be used!
- the agent for promoting self-renewal of stem cells of the present invention can promote self-renewal of stem cells when brought into contact with stem cells in vivo and in vitro.
- the stem cells are not particularly limited as long as they are stem cells present in adult tissues (adult stem cells), but are preferably stem cells present in bone marrow, peripheral blood, skin, adipose tissue, skeletal muscle, and the like.
- the activity of inhibiting the production of active oxygen in the stem cell is a drug that can be used alone as it is as a stem cell self-renewal promoter. It is desirable to mix it with one or more carriers that are physically acceptable and provide it as a pharmaceutical preparation produced by any method well known in the pharmaceutical arts.
- Examples of the administration form include tablets, capsules, granules, injections, ointments, tapes, inhalants such as dry powders and aerosols.
- excipients such as lactose, disintegrants such as starch, lubricants such as magnesium stearate, binders such as hydroxypropylcellulose, fatty acid esters and the like
- binders such as hydroxypropylcellulose, fatty acid esters and the like
- surfactants and plasticizers such as glycerin can be used.
- Formulations suitable for intramuscular, subcutaneous, intradermal, intravenous or intratracheal administration include, for example, injections, sprays and the like.
- water for example, water, physiological saline, vegetable oils such as soybean oil, solvents, solubilizers, isotonic agents, preservatives, antioxidants and the like can be used.
- the inhalant is prepared using the substance of the present invention or a carrier which does not irritate the oral and respiratory mucosa of the recipient, disperses the substance as fine particles, and facilitates absorption.
- the carrier include lactose, glycerin and the like. Preparations such as aerosols and dry powders are possible depending on the properties of the substance and the carrier used in the present invention. Also, in these parenteral preparations, the components exemplified as additives in the oral preparation can be added.
- the dose or the number of administrations varies depending on the desired prophylactic or therapeutic effect, the administration method, the administration period, the age, the body weight, etc., but is usually 20 to 25 mg for vitamin B12 and 20 to 25 mg for vitamin C per adult per day. 200-1000 mg, vitamin E 400-800 IU, carotenoids 5-60 mg, ubiquinone 30-150 mg, N-acetylcystine 250-1500 mg, glutathione 500-1000 mg, polyphenols l-1000 mg, curcumin
- tetrahydrocurcumin is administered at 10 to 1000 mg, and SB203580, SB202190, PD169316, FR167653, and BIRB796BS at 100 to 1000 g, respectively.
- the stem cell self-renewal promoter of the present invention can promote self-renewal of the stem cells by contacting the stem cells in vitro and culturing the stem cells.
- the agent for promoting self-renewal of stem cells of the present invention is used in vitro
- the substance of the present invention is preferably dissolved in a solution capable of dissolving the substance before use.
- the solution may be water, Rusulfoxide (DMSO) and the like.
- tissues from which stem cells can be separated include bone marrow, peripheral blood, skin, adipose tissue, skeletal muscle, and the like.
- CD45-negative and glycophorin-A-negative cells were selected from cells isolated from these tissues by enzyme treatment, etc., and 10 ⁇ g / ml insulin, 5.5 ⁇ g / ml using Low-GLUCOSE DMEM, MCDB-201, etc. as a basic medium.
- Transferrin 5 ng / ml selenium, 0.5 ⁇ g / ml bovine serum albumin, 0.01 ⁇ mol / 1 dexamethasone, 0.1 mmol / l L-ascorbic acid diphosphate, 2% fetal bovine serum, lOng / ml platelet-derived growth factor, lOng 5 ng / ml using a medium containing epidermal growth factor, lOng / ml insulin-like growth factor, 1000 IU leukemia inhibitory factor and the substance of the present invention, or DMEM medium containing 10% horse serum and the substance of the present invention.
- DMEM medium containing 10% horse serum and the substance of the present invention.
- the concentration of the substance of the present invention in the medium used in the above culture is adjusted according to the density of the cells to be cultured.
- the equipment used is a completely closed system capable of concentrating, washing and recovering cultured cells. It is preferable that the cultured cells be washed with a physiological saline solution using Hemolite 2 Plus or the like to remove as much as possible the substances such as cytodynamics used for culture!
- the stem cell self-renewal promoting activity of the stem cell self-renewal promoting agent of the present invention can be evaluated, for example, by the following method.
- the stem cell self-renewal promoting agent of the present invention is administered to a non-human animal with reduced stem cell self-renewal ability, and the stem cell self-renewal promoting ability of the non-human animal is measured.
- the activity of promoting self-renewal of stem cells can be evaluated.
- Stem cell self-renewal ability is determined by observing the reduction in symptoms associated with reduced stem cell self-renewal ability, or by culturing stem cells isolated from the animal in the presence of the stem cell self-renewal promoter of the present invention. It can be measured, for example, by measuring colony forming ability.
- an ATM homo-deficient mouse As a non-human animal with reduced self-renewal ability of stem cells, for example, an ATM homo-deficient mouse can be used.
- the self-replicating ability was decreased due to an increase in the amount of intracellular active oxygen of hematopoietic stem cells, and as a result, myeloid cells, lymphoid cells, erythroid cells, etc. were remarkably reduced, and hematopoietic stem cell colonies were formed. Performance is significantly reduced.
- the stem cell self-renewal promoter of the present invention when an ATM homo-deficient mouse is used as a non-human animal with reduced stem cell self-renewal ability, after administering the stem cell self-renewal promoter of the present invention to the mouse, the anemia state is reduced by flow cytometry.
- the stem cell self-renewal promoting activity of the stem cell self-renewal promoter of the present invention can be evaluated.
- cells containing hematopoietic stem cells such as osteoclasts collected from the mice, c-Kit positive, Sca-1 positive and Lineage negative cells (KSL cells) separated by the bone marrow cell force FACS sorter or the like.
- KSL cells Lineage negative cells
- the self-renewal ability of cells including hematopoietic stem cells derived from ATM homo-deficient mice was measured by the above method, and the presence of the test substance and the absence of the test substance were measured.
- the self-renewal ability of the cells in the presence of the test substance is compared, and the self-renewal ability in the presence of the test substance is enhanced more than the self-renewal ability in the absence of the test substance!
- a hematopoietic stem cell self-replication promoter can be screened.
- the agent for promoting stem cell self-renewal of the present invention has an effect of preventing senescence of stem cells, and therefore can be used as a preventive agent for cancer whose onset frequency increases with aging and diseases associated with tissue destruction.
- the agent for promoting self-renewal of stem cells of the present invention promotes tissue repair by promoting self-renewal of stem cells and bone marrow stem cells of injured tissues, and is therefore a therapeutic agent for diseases associated with tissue destruction.
- diseases associated with tissue destruction include neurological diseases, cardiovascular diseases, liver diseases, spleen Disease, digestive tract disease, kidney disease, skin disease, lung disease and the like.
- Examples of the neurological disease include cerebral infarction, cerebrovascular disease, Parkinson's disease, Aln's disease, Huntington's chorea, spinal cord injury, depression, and manic depression.
- Examples of the circulatory system disease include obstructive vascular disease, myocardial infarction, heart failure, coronary artery disease and the like.
- liver disease examples include hepatitis B, hepatitis C, alcoholic hepatitis, cirrhosis, liver failure and the like.
- Examples of the spleen disease include diabetes, spleenitis and the like.
- Gastrointestinal diseases include, for example, Crohn's disease, ulcerative colitis and the like.
- kidney disease examples include IgA nephropathy, nephritis, renal failure and the like.
- Skin diseases include, for example, pressure sores, burns, suture wounds, lacerations, incision wounds, bites, dermatitis, hypertrophic scars, keloids, diabetic ulcers, arterial ulcers, venous ulcers and the like.
- lung diseases include emphysema, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic interstitial pneumonia (pulmonary fibrosis), diffuse pulmonary fibrosis, tuberculosis, and asthma. It is.
- the agent for promoting self-renewal of stem cells of the present invention promotes self-renewal widely to stem cells present in adult tissues, and thus can be used as a therapeutic agent for tissue failure associated with various diseases. That is, the agent for promoting self-renewal of stem cells of the present invention promotes the self-renewal of stem cells present in a tissue in which a tissue failure has occurred, thereby promoting the renewal of cells forming the tissue and treating the tissue failure. be able to.
- Diseases associated with tissue failure include, for example, bone marrow failure, motor dysfunction, circulatory disease, neurological disease, pressure ulcer, osteoporosis, arthritis, lung disease, gastrointestinal tract disease, alveolar pyorrhea, liver disease Patients, spleen disease, kidney disease, endocrine abnormalities, retinal disorders, cataracts, hearing loss and the like.
- the cells stimulated by the stem cell self-renewal promoting agent of the present invention include, for example, red blood cells, white blood cells, and platelets in bone marrow failure, and fibroblasts, adipocytes, and skeletal muscle in motor dysfunction.
- Cells smooth muscle cells, cardiomyocytes, vascular endothelial cells for cardiovascular diseases, neurons-euron, glia, oligodendrocytes, skin for pressure ulcers Skin epidermal cells, skin dermal cells, hair follicle cells, osteocytes, osteoblasts, osteoclasts for osteoporosis, chondrocytes for arthritis, tracheal epithelial cells, alveolar cells for lung disease, gastrointestinal tract for gastrointestinal diseases
- Epithelial cells oral epithelial cells for alveolar pyorrhea, enamel blast cells, zoege blast cells, hepatocytes for liver disease, Kupffer cells, gallbladder epithelial cells, endocrine spleen cells for spleen disease, exocrine spleen cells for kidney disease, kidney tubule for kidney disease Cells, renal glomerular cells, ureteral epithelial cells, urothelial cells, pituitary secretory cells, thyroid cells,
- the stem cells self-replicated in vitro using the stem cell self-renewal promoting agent of the present invention according to the method described in 1 above can be injected into a vein by a normal infusion method or directly into an affected part by injection. It can be used for the prevention or treatment of each of the above diseases.
- stem cell self-renewal promoter of the present invention in combination with a GSK-3 inhibitor, HGF, G-CSF, M-CSF, GM-CSF
- the agent for promoting self-renewal of stem cells of the present invention includes a glycogen synthase kinase-3 (GSK-3) inhibitor and hepatocyte growth factor (HGF) that promote proliferation and differentiation of stem cells, and mobilization, proliferation, and distribution of stem cells.
- G-CSF granulocyte colony stimulating factor
- M-CSF macrophage colony stimulating factor
- GM-CSF granulocyte 'macrophage colony stimulating factor
- GSK-3 inhibitors include L803-mts (Biol Psychiatry. 2004 Apr 15; 55: 781-4.) And macrocyclic bis-7-azaindolylmaleimides (Bioorg Med Chem. 2004 Mar 12: 1239-55). ), 6-bromoindiruDin-3′-oxime (Nat Med. 2004 Jan 0: 55-63.), 1-azakenpaullone (Bioorg Med Chem Lett. 2004 Jan 19; 14: 413-6) and the like.
- the G-CSF for example Nartograstim (trade name Noiappu, Kyowa Hakko Kogyo Co., Ltd.), off Irugurasuchimu (trade name Gran, Sankyo Co., Ltd .; trade name Granulokine, Hoffman 'La' Roche Ltd .; trade name Ne U p Gen , Amdion), Lenograstim (trade name Neutrogin, manufactured by Chugai Pharmaceutical Co., Ltd .; Granocyte, Aventis), pegfilgrastim (trade name Neulasta, Amge) Sargramostim (trade name Leukine, manufactured by Schering) and the like.
- Nartograstim trade name Noiappu, Kyowa Hakko Kogyo Co., Ltd.
- off Irugurasuchimu trade name Gran, Sankyo Co., Ltd .
- trade name Granulokine Hoffman 'La' Roche Ltd .
- Ne U p Gen Amdion
- Lenograstim trade name Neutrogin, manufactured by Ch
- M-CSF examples include Millimostim (trade name of Leukoprol, manufactured by Kyowa Hakko Kogyo Co., Ltd.) and the like.
- GM-CSF examples include romultide (trade name: Nopia Note, manufactured by Daiichi Pharmaceutical Co., Ltd.) and the like.
- the agent for promoting self-renewal of stem cells and the concomitant components of the present invention may be used as a single agent (combination) or in a combination of a plurality of preparations as long as they are formulated so as to contain these respective active ingredients.
- the preparation method, administration form, administration method and the like of the preparation can be performed in the same manner as in the above 1.
- kits When administered as a combination of a plurality of preparations, for example, (a) a first component containing a stem cell self-renewal promoter and (b) a second component containing a combination component are separately formulated.
- a kit can be prepared and each component can be administered to the same subject by the same route or different routes at the same time or at a certain time using the kit.
- the kit may be made of, for example, any material or shape as long as it is a container that does not show denaturation of its components due to external temperature or light during storage or elution of chemical components from the container. It is composed of two or more containers (eg, vials, bags, etc.) and contents without limitation, and the above-mentioned first and second components, which are contents, are administered via separate routes (eg, tubes, etc.) or via the same route. Those having a possible form are used. Specifically, kits for tablets, injections, inhalants and the like can be mentioned.
- the preferred U ⁇ dose ratio (weight Z weight) of the stem cell self-renewal promoter and the concomitant component is appropriately adjusted according to the combination of the stem cell self-renewal promoter and the concomitant component used, the potency of the concomitant component, and the like. For example, it is used at a dose ratio of lZ5000 to 100Zl, preferably 10000 to 20 ⁇ , more preferably ⁇ .
- the dose or the number of administrations varies depending on the desired preventive or therapeutic effect, administration method, period, age, body weight, and the like.
- the dose described in 1 above, and for the GSK-3 inhibitor Usually, it is preferable to administer 0.1 mgZkg to 100 mgZkg per adult per day, and for HGF, G-CSF, M-CSF or GM-CSF, usually 0.1 mgZkg to 100 gZkg per adult per day.
- Test Example 1 Increased amount of active oxygen and decreased self-renewal ability in ATM homo-deficient mouse hematopoietic stem cells
- the ATM homo-deficient mouse is the same as the male and female of the ATM hetero-deficient mouse obtained from Dr. Peter McKinnon at St. Jude Children's Research Hospital. Obtained by Litters of wild-type mice (C57B L / 6-Ly5.2) were used as a control.
- the recovered bone marrow cell strength was also determined by FACS sorter and anti-c-Kit antibody (BD Regngen, 2B8), anti-Sea-1 antibody (BD Regngen, D7), anti-CD4 antibody (BD Regngen, L3T4) , Anti-CD8 antibody (BD Regngen, 53-6.72), anti-B220 antibody (BD Regngen, RA3-6B2), anti-TER-119 antibody (BD Regngen), anti-Gr-1 antibody (BD POngen RB6- 8 C5) and anti-Mac-1 antibody (BD Regngen, M1 / 70) using c-Kit positive, Sea-1 positive and Lineage negative cells (KSL cells), Lineage negative cells and Lineage positive cells were separated.
- the lineage negative cells include CD4 and CD8, T cell markers, B220, B cell markers, TER-119, a red blood cell marker, Gr-1, a granulocyte marker, and macrophages.
- Lineage-positive cells are cells that are positive for at least one of these markers. Means vesicle.
- the bone marrow remodeling ability at one month after transplantation showed no significant difference between cells derived from ATM homo-deficient mice and cells derived from wild-type mice.
- the number of cells derived from ATM homo-deficient mice decreased significantly. This tendency was more remarkably observed when KSL cells, an undivided cell population, were transplanted.
- failure of bone marrow remodeling was observed in all three lineages of B cells, T cells, and myeloids.
- ATM homo-deficient mice frequently develop lymph tumors after 8 weeks of age, but some mice survive for a long time without developing lymph tumors. Observation of such long-term surviving ATM home-deficient mice revealed that they exhibited severe anemia after 20 weeks of age, unlike wild-type mice.
- KSL cells derived from ATM homo-deficient mice had about 15 to 20-fold increase in KSL cells derived from wild-type mice. Furthermore, after culturing for 2 days in the presence of SCF and TPO, the amount of active oxygen in the cells was measured.As a result, KSL cells derived from ATM homo-deleted mice were approximately 40 to 50 times more than wild-type mice. Also reached. When the changes in the gene expression of KSL cells due to vigorous culture were analyzed by RT-PCR, a remarkable increase in the expression of pl6I NK4a gene was observed.
- Test Example 2 Recovery of reduced self-renewal ability in hematopoietic stem cells from ATM homo-deficient mice by administration of an antioxidant
- the cells were collected, and on methylcellulose, 20 ng / ml SCF, 20 ng / ml IL-3 (manufactured by PeproTech EC) and 2 U / ml erythropoietin (manufactured by Chugai Pharmaceutical) A mouth-one formation test was performed in the presence of.
- hematopoietic stem cells contained in KSL cells need to self-renew.
- NAC and catalase-added koji reduced the amount of active oxygen in hematopoietic stem cells and restored the self-renewal ability of the stem cells.
- NAC was subcutaneously administered to the ATM homo-deficient mouse at a dose of 100 mg / kg / day for 3 weeks, and the amount of active oxygen in the KSL cells isolated from the bone marrow of the mouse by the above method was measured. As a result, it was equal to the amount of active oxygen in KSL cells derived from wild-type mice.
- a competitive bone marrow reconstitution test using the method described in Test Example 1 using KSL cells derived from ATM homo-deficient mice to which NAC was administered, unlike the control group that received NAC, Hematopoietic recovery was observed.
- An injection having the following composition is prepared by a conventional method.
- An injection having the following composition is prepared by a conventional method.
- a stem cell self-replication promoter a prophylactic agent for cancer, a prophylactic or therapeutic agent for a disease or tissue failure accompanied by tissue destruction, and a culture medium for stem cell culture to which the stem cell self-replication promoter is added
- the present invention also provides a stem cell cultured in the medium, a method for producing a stem cell, or a method for screening a hematopoietic stem cell self-renewal promoter.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006514572A JPWO2005121320A1 (ja) | 2004-06-10 | 2005-06-10 | 幹細胞自己複製促進剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004172057 | 2004-06-10 | ||
JP2004-172057 | 2004-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005121320A1 true WO2005121320A1 (ja) | 2005-12-22 |
Family
ID=35503058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/010642 WO2005121320A1 (ja) | 2004-06-10 | 2005-06-10 | 幹細胞自己複製促進剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005121320A1 (ja) |
WO (1) | WO2005121320A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009539546A (ja) * | 2006-06-15 | 2009-11-19 | アールエヌエル バイオ カンパニー,リミティッド | ヒト脂肪組織由来成体幹細胞、繊維芽細胞、及び脂肪又は脂肪細胞を含有する皮膚美容又は形成用の組成物 |
JP2012511935A (ja) * | 2008-12-17 | 2012-05-31 | ザ スクリプス リサーチ インスティチュート | 幹細胞の作製と維持 |
JP2013209302A (ja) * | 2012-03-30 | 2013-10-10 | Kose Corp | リンゴ幼果抽出物を含む表皮幹細胞性維持剤 |
JP2015527083A (ja) * | 2012-09-07 | 2015-09-17 | チルドレンズ メディカル センター コーポレーション | 造血幹細胞特異的レポーターマウスおよびその使用 |
WO2018034314A1 (ja) * | 2016-08-18 | 2018-02-22 | 北海道公立大学法人札幌医科大学 | 間葉系幹細胞活性化剤 |
CN113226338A (zh) * | 2019-01-16 | 2021-08-06 | Scm生命科学有限公司 | 包含克隆干细胞的用于预防或治疗特应性皮炎的药学组合物 |
JP2022528033A (ja) * | 2019-03-19 | 2022-06-08 | エスシーエム ライフサイエンス カンパニー リミテッド | 単一クローナル幹細胞を用いたアトピー皮膚炎の治療方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101365430B (zh) * | 2006-01-27 | 2011-09-21 | 坎-菲特生物药物有限公司 | 用于治疗干眼病的腺苷a3受体激动剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002029011A2 (fr) * | 2000-10-06 | 2002-04-11 | Igr Et D | Utilisation d"une composition a activite antioxydante pour le conditionnement de cellules souches |
-
2005
- 2005-06-10 WO PCT/JP2005/010642 patent/WO2005121320A1/ja active Application Filing
- 2005-06-10 JP JP2006514572A patent/JPWO2005121320A1/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002029011A2 (fr) * | 2000-10-06 | 2002-04-11 | Igr Et D | Utilisation d"une composition a activite antioxydante pour le conditionnement de cellules souches |
Non-Patent Citations (12)
Title |
---|
BAGLEY J. ET AL: "Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice", BLOOD, vol. 104, 15 July 2004 (2004-07-15), pages 572 - 578, XP002992011 * |
BARLOW-WALDEN L.R. ET AL: "Melatonin stimulates brain glutathione peroxidase activity", NEUROCHEM. INT., vol. 26, no. 5, 1995, pages 497 - 502, XP004739624 * |
BROWNE S.E. ET AL: "Treatmenbt with a catalytic antioxidant corrects the neurobehavioral defect in Ataxia-telangiectasia mice", FREE RADICAL BIOLOGY & MEDICINE, vol. 36, April 2004 (2004-04-01), pages 938 - 942, XP002992012 * |
CHEN P. ET AL: "Oxidative stress is responsible for deficient survival and dendritogenesis in punrkinje neurons from Ataxia-telangiectasia mutated mutant mice", THE JOURNAL OF NEUROSCIENCE, vol. 23, 2003, pages 11453 - 11460, XP002992013 * |
FORMICHI P. ET AL: "Apoptotic response and cell cycle transition in Ataxia telangiectasia cells exposed to oxidative stress", LIFE SCIENCES, vol. 66, 2000, pages 1893 - 1903, XP002992016 * |
ITO K. ET AL: "Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells", NATURE, vol. 431, 21 October 2004 (2004-10-21), pages 997 - 1002, XP002992010 * |
KAMSLER A. ET AL: "Increased oxidative stress in Ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice", CANCER RESEARCH, vol. 61, 2001, pages 1849 - 1854, XP002992015 * |
KASHIWAKURA I. ET AL: "Effects of alpha-phenyl N-tert-butylnitrone, a spin trap reagent, on the proliferation of murine hematopoietic progenitor cells in vitro", RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, vol. 98, no. 1, 1997, pages 67 - 76, XP002992008 * |
MORSHEAD C.M. ET AL: "A cell-survival factor (N-acetyl-L-cysteine) alters the in vivo fate of constitutively proliferating subependymal cells in the adult forebrain", JOURNAL OF NEUROBIOLOGY, vol. 42, no. 3, 2000, pages 338 - 346, XP001011897 * |
PETER Y. ET AL: "Elevated Cu/Zn-SOD exacerbates radiation sensitivity and hematopoietic abnormalities of Atm-deficient mice", THE EMBO JOURNAL, vol. 20, 2001, pages 1538 - 1546, XP002992014 * |
TAKAO N. ET AL: "Protective roles for ATM in cellular response to oxidase stress", FEBS LETTERS, vol. 472, 2000, pages 133 - 136, XP004337056 * |
ZAFARULLAH M. ET AL: "Molecuar mechanisms of N-acetylcysteine actions", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 60, 2003, pages 6 - 20, XP002992009 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009539546A (ja) * | 2006-06-15 | 2009-11-19 | アールエヌエル バイオ カンパニー,リミティッド | ヒト脂肪組織由来成体幹細胞、繊維芽細胞、及び脂肪又は脂肪細胞を含有する皮膚美容又は形成用の組成物 |
JP2012511935A (ja) * | 2008-12-17 | 2012-05-31 | ザ スクリプス リサーチ インスティチュート | 幹細胞の作製と維持 |
JP2016052305A (ja) * | 2008-12-17 | 2016-04-14 | ザ スクリプス リサーチ インスティテュート | 幹細胞の作製と維持 |
JP2013209302A (ja) * | 2012-03-30 | 2013-10-10 | Kose Corp | リンゴ幼果抽出物を含む表皮幹細胞性維持剤 |
JP2015527083A (ja) * | 2012-09-07 | 2015-09-17 | チルドレンズ メディカル センター コーポレーション | 造血幹細胞特異的レポーターマウスおよびその使用 |
US10080354B2 (en) | 2012-09-07 | 2018-09-25 | Children's Medical Center Corporation | Hematopoietic stem cell specific reporter mouse and uses thereof |
WO2018034314A1 (ja) * | 2016-08-18 | 2018-02-22 | 北海道公立大学法人札幌医科大学 | 間葉系幹細胞活性化剤 |
CN113226338A (zh) * | 2019-01-16 | 2021-08-06 | Scm生命科学有限公司 | 包含克隆干细胞的用于预防或治疗特应性皮炎的药学组合物 |
JP2022517983A (ja) * | 2019-01-16 | 2022-03-11 | エスシーエム ライフサイエンス カンパニー リミテッド | クローナル幹細胞を含むアトピー皮膚炎の予防または治療用薬学的組成物 |
JP7493814B2 (ja) | 2019-01-16 | 2024-06-03 | エスシーエム ライフサイエンス カンパニー リミテッド | クローナル幹細胞を含むアトピー皮膚炎の予防または治療用薬学的組成物 |
JP2022528033A (ja) * | 2019-03-19 | 2022-06-08 | エスシーエム ライフサイエンス カンパニー リミテッド | 単一クローナル幹細胞を用いたアトピー皮膚炎の治療方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005121320A1 (ja) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005121320A1 (ja) | 幹細胞自己複製促進剤 | |
KR102019277B1 (ko) | 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물 | |
US11110126B2 (en) | Method of expanding NK cell and composition for culturing | |
US20080241115A1 (en) | Use Of Mesenchymal Stem Cells Genetically Modified To Express A Suicide Gene For Treating A Cancer | |
JP6894652B1 (ja) | 組織修復剤、組織修復剤の使用方法およびスクリーニング方法 | |
WO2016049867A1 (zh) | 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法 | |
Kim et al. | Stress-associated erythropoiesis initiation is regulated by type 1 conventional dendritic cells | |
JPWO2004101775A1 (ja) | 新規な成体組織由来の幹細胞およびその用途 | |
US20170065640A1 (en) | In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs | |
WO2024070382A1 (ja) | 微小粒子、nk細胞活性化剤、nk細胞の培養方法、活性化nk細胞の製造方法およびnk細胞の活性化方法 | |
NZ537072A (en) | Primary cultured adipocytes for gene therapy to which a foreign gene has been transferred | |
KR20190074720A (ko) | 골수이식 후 생착 촉진용 조성물 | |
EP4349348A1 (en) | Cancer cachexia ameliorating agent and cancer cachexia amelioration method | |
EP4212163A1 (en) | Cytokine storm inhibitor, method for using cytokine storm inhibitor, and method for screening for cytokine inhibitor | |
KR102446146B1 (ko) | 근육 유래 미토콘드리아를 포함하는 면역질환의 예방 또는 치료용 조성물 | |
EP3950934A1 (en) | Method for culturing cell population and use thereof | |
Sun et al. | Conditioned medium from human cord blood mesenchymal stem cells attenuates age-related immune dysfunctions | |
US20190151358A1 (en) | P53 silenced endothelial progenitor cells for diabetes | |
KR20200132550A (ko) | 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 혈관질환 예방 또는 치료용 조성물 | |
TW201609115A (zh) | 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法 | |
WO2024085261A1 (ja) | 微小粒子、勃起不全の予防薬または治療薬および勃起不全の改善方法 | |
EP4238572A1 (en) | Osteogenic composition and use thereof | |
KR102526447B1 (ko) | 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 간질환 예방 또는 치료용 조성물 | |
KR102037996B1 (ko) | 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 제2형 당뇨병 예방 또는 치료용 조성물 | |
KR20190092348A (ko) | 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006514572 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |